Nyrada
Menu
NYR:
Market Cap*:
Price Delay ~20min
Home
About Us
Company Overview
Board of Directors
Management
Scientific Advisory Board
Corporate Governance
Investors
Investor Welcome
Company Fact Sheet
ASX Announcements
Neuroprotection Program
Cardioprotection Program
Financial Reports
Corporate Announcements
Investor Presentations
Share Price Information
Key Dates
Investors Glossary
Annual Reports
Analyst Reports
Annual General Meeting
Extraordinary General Meeting
Past Shareholder Meetings
News & Insights
Presentations & Interviews
Media
Newsletters
Publications
Contact Us
Contact Us
Working at Nyrada
Email Alerts
News & Insights
Home
>
News & Insights
>
Media
Presentations & Interviews
Media
Newsletters
Publications
Media
Filter by Year:
2024
2021
2020
28-Oct-2024
Nyrada raises $3.36 million to support drug discovery
17-Oct-2024
Nyrada says it has completed safety studies ahead of Phase 1 clinical trial
16-Oct-2024
Health Check: Rats – and investors – are happy as Nyrada forges ahead with its first human brain injury trial
16-Oct-2024
Nyrada gears up for Phase I clinical trials
7-Oct-2024
Tony’s Takeaway: Biotech buffet on the ASX - Stockhead TV
7-Oct-2024
Nyrada progresses brain injury programme studies
4-Oct-2024
Bulls'n'Bears ASX Runners of the Week
2-Oct-2024
Nyrada’s NYR-BI03 shows significant cardioprotective efficacy in preclinical study
1-Oct-2024
Nyrada Shares Surge After Lead Drug Candidate Demonstrates Significant Cardioprotection
20-Aug-2024
Nyrada’s NYR-BI03 shows safety in rats; Phase I planned for late 2024
1
2
Next
